Chemoprevention in barrett's esophagus

被引:2
|
作者
Ilyas S. [1 ]
Demars C.J. [1 ]
Buttar N.S. [1 ,2 ]
机构
[1] Department of Internal Medicine, Division of Gastroenterology and Hepatology, Mayo Graduate School of Medicine, Rochester, MN
[2] Gastroenterology Research Unit and Barrett's Esophagus Unit, Rochester, MN 55902
关键词
Adenocarcinoma of esophagus; Barrett's esophagus; Carcinogenesis; Chemoprevention; Signaling;
D O I
10.1007/s12029-007-9006-7
中图分类号
学科分类号
摘要
Barrett's metaplasia-associated esophageal adenocarcinoma is one of the most rapidly increasing cancers in Western countries. Whereas early detection remains the cornerstone of prevention, chemoprevention is emerging as a complementary strategy. Carcinogenesis in Barrett's mucosa is a multistep process in which cellular growth becomes progressively dysregulated. Fortunately, the process of carcinogenesis is a protracted one, which provides ample opportunity for intervention. In this review, we will discuss various potential chemoprevention targets and rationale behind their use to prevent Barrett's related esophageal adenocarcinoma. We will also critically appraise the emerging preclinical and clinical literature regarding prevention of neoplasia in Barrett's esophagus. © 2007 Humana Press Inc.
引用
收藏
页码:1 / 9
页数:8
相关论文
共 50 条
  • [21] Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus
    Jankowski, J
    Moayyedi, P
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11): : 885 - 887
  • [22] The role of chemoprevention in Barrett esophagus and esophageal adenocarcinoma
    Wani, Sachin
    Sharma, Prateek
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (06) : S135 - S140
  • [23] Cost-Effectiveness of Chemoprevention with Proton Pump Inhibitors in Barrett's Esophagus
    Sharaiha, Reem Z.
    Freedberg, Daniel E.
    Abrams, Julian A.
    Wang, Y. Claire
    DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (06) : 1222 - 1230
  • [24] Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus - Response
    Hur, C
    Nishioka, N
    Gazelle, GS
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (11) : 887 - 887
  • [25] Cost-Effectiveness of Chemoprevention with Proton Pump Inhibitors in Barrett’s Esophagus
    Reem Z. Sharaiha
    Daniel E. Freedberg
    Julian A. Abrams
    Y. Claire Wang
    Digestive Diseases and Sciences, 2014, 59 : 1222 - 1230
  • [26] ADHERENCE TO GUIDELINES FOR SURVEILLANCE AND CHEMOPREVENTION OF NON-DYSPLASTIC BARRETT'S ESOPHAGUS
    Khan, Tanya
    Kraft, Cary
    Leet, Donna
    Libuit, Erin
    Xu, Chelsea
    Dalal, Nicole
    Pierce, Logan
    Ravi, Akshay
    Ko, Myung S.
    Kathpalia, Priya
    GASTROENTEROLOGY, 2023, 164 (06) : S514 - S515
  • [27] Gastroenterology Barrett's Esophagus: Chemoprevention with PPI cost-effective for all Patients
    Foede, Mark
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2014, 19 (05): : 202 - 202
  • [28] Cost-Effectiveness of Chemoprevention With and Without Proton Pump Inhibitors in Barrett's Esophagus
    Sharaiha, Reem Z.
    Wang, Y. Claire
    Neugut, Alfred I.
    Abrams, Julian A.
    GASTROENTEROLOGY, 2011, 140 (05) : S204 - S205
  • [29] Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis
    Choi, Sung Eun
    Perzan, Katherine E.
    Tramontano, Angela C.
    Kong, Chung Yin
    Hur, Chin
    CANCER PREVENTION RESEARCH, 2014, 7 (03) : 341 - 350
  • [30] Chemoprevention in Barrett's oesophagus
    Gordon, Victoria
    Jankowski, Janusz
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2011, 25 (4-5) : 569 - 579